About this notebook
Who publishes this site, what we do, and what we deliberately do not do.
Who publishes this site
Legit Sermorelin is a reading binder for sermorelin (GHRH 1-29) — the peer-reviewed studies and the regulatory record annotated page by page, the way you would keep an evidence binder on a contested subject. No clinic sits behind the binder; no one here sees patients, prescribes, or gives medical advice. It makes nothing, sells nothing, and ships nothing. It reads the published literature and the FDA paper trail, and writes down what each one actually says.
The word "legit" in the domain is a reference to the most common search query that brings readers here — people asking whether sermorelin is a real peptide with a real regulatory history, or a marketing fiction. It is editorial framing for the publisher's position relative to the literature, not a claim about clinical services. We do not run a pharmacy, a telehealth practice, or a prescribing service of any kind.
What we cover, and what we do not
We cover: the molecule and its mechanism, the FDA regulatory record (the 1990 diagnostic NDA, the 1997 pediatric NDA, the 2008 commercial discontinuation, the 2013 Federal Register determination, and the current Section 503A compounding status), the published clinical trials in pediatric GHD and age-advanced adults, pharmacokinetics, the 2012 cognition trial, and the 2021 computational glioma screening result. We summarise tolerability as reported in the original registration record.
We do not cover: clinical decision-making for any individual reader. We do not provide dosing recommendations for human use. We do not endorse any compounding pharmacy, vendor, telehealth practice, or product. We do not speculate beyond the published record. When the literature is sparse — for example, on long-term outcomes in healthy adults — we say so.
Sourcing and editorial standards
Every quantitative claim on this site cites a specific paper, FDA document, or review. The primary sources include PubMed-indexed clinical trials (Vittone 1997, Khorram 1997, Khorram-immune 1997, Baker 2012), peer-reviewed reviews (Prakash & Goa 1999, Yuen 2009, Ishida 2020), the FDA Federal Register notice (2013), the FDA PCAC briefing materials (2024-2025), and a 2025 regulatory legal analysis. Where a study used a sermorelin-class GHRH(1-29) analog rather than sermorelin acetate itself, we note that explicitly. Where a finding rests on computational rather than clinical work, we note that as well.
We do not cite vendor websites, social-media threads, or anonymous forum posts. We do not invent studies. If a claim is not in the research file that anchors this notebook, it does not appear in the body copy.
What this site is not
This site is not a clinic, not a pharmacy, not a telehealth service, not a vendor, and not affiliated with any of the above. We do not employ doctors, pharmacists, or nurses. We do not maintain a clinical staff. There is no physical address, no phone line, and no consultation booking on this site by design — adding any of those would misrepresent what the publisher actually does, which is read and summarise the published literature on a single peptide.
The domain modifier "legit" is editorial. It signals the publisher's relationship to a contested search query, not a claim about services. If you came here looking for medical advice, you came to the wrong place; we are a reading binder, not a clinician.